Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Forster on Recent Data With Lurbinectedin in SCLC

October 8th 2018

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses data of lurbinectedin plus doxorubicin as a second-line therapy for patients with small cell lung cancer.

Dr. Spigel Reflects on the PACIFIC Study in NSCLC

October 5th 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

Dr. Naidoo on the Mechanisms Behind Immune-Related Adverse Events in Lung Cancer

October 4th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the mechanisms behind immune-related adverse events (irAEs) in lung cancer.

Dr. Liu on Sequencing Therapy in ALK-Positive NSCLC

October 2nd 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses sequencing strategies for patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Pacheco on Frontline Therapy for Patients With EGFR-Mutant NSCLC

September 29th 2018

Jose M. Pacheco, MD, an assistant professor of medicine/medical oncology at the Colorado University School of Medicine, discusses frontline therapy for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Bauml on Treatment For Oligometastatic NSCLC

September 28th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the treatment of patients with oligometastatic non–small cell lung cancer.

Dr. Kris on the FDA Approval of Dacomitinib in EGFR+ NSCLC

September 28th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.

FDA Approves Dacomitinib for Frontline EGFR+ NSCLC

September 28th 2018

The FDA has approved dacomitinib (Vizimpro) for the frontline treatment of patients with metastatic non–small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

Dr. Gandara on Online Treatment Decision Tool for Lung Cancer

September 27th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), a 2017 Giant of Cancer Care® in Lung Cancer, discusses the idea for an online treatment decision tool for lung cancer.

Cell-Free DNA Sequencing Could Help Early Detection of Lung Cancer

September 27th 2018

Geoffrey R. Oxnard, MD, discusses the promise of genome-wide sequencing in cell-free DNA.

Dr. Heifetz Discusses Rural Oncology Care

September 26th 2018

Laurence J. Heifetz, MD, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses rural oncology care.

Lurbinectedin Combo Induces Clinical Activity in Chemo-Sensitive SCLC

September 26th 2018

Lurbinectedin plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer, especially when excluding refractory patients.

Entinostat/Pembrolizumab Combo Shows Promise in NSCLC Subgroup

September 26th 2018

Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes.

Dr. Pennell on the Cost Effectiveness of NGS in NSCLC

September 26th 2018

Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the cost-effectiveness of next-generation sequencing for patients with metastatic non–small cell lung cancer.

Atezolizumab Prolongs Survival in SCLC

September 26th 2018

The addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone.

Brigatinib Bests Standard of Care to Improve PFS in Advanced NSCLC

September 25th 2018

Brigatinib reduced the risk of disease progression or death by more than 50% compared to crizotinib in adult patients with ALK-positive, locally advanced or metastatic NSCLC.

Adding Durvalumab to Chemoradiation Improves OS in Unresectable Stage III NSCLC

September 25th 2018

Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.

Atezolizumab Regimen Improves PFS in Frontline Nonsquamous NSCLC

September 25th 2018

The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC.

Neoadjuvant Immunotherapy May Change Standard of Care in Early-Stage NSCLC

September 25th 2018

Wade T. Iams, MD, and Erin A. Gillaspie, MD, MPH, discuss the impact that immunotherapy has had on the treatment of patients with early-stage non–small cell lung cancer.

Repotrectinib Shows Promising Activity in ROS1+ NSCLC

September 25th 2018

Repotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive NSCLC.